ArticleFrontiers in medicine2026
Night-to-night sleep variability and all-cause and cardiovascular mortality: a prospective cohort study with a complementary
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Irregular sleep-wake patterns may disrupt circadian rhythms, but the dose-response relationship between night-to-night sleep variability and mortality and the association of sleep onset variability with death remain unclear. Methods: Using 4-7 valid days of wrist accelerometer data, including ≥1 weekend day, from 7,604 adults aged ≥20 years in the National Health and Nutrition Examination Survey 2011-2014, linked to mortality through December 2019, we examined the within-person SDs of sleep midpoint, sleep onset, and total sleep time across nights and the sleep regularity index (SRI) in relation to all-cause and cardiovascular disease (CVD) mortality. Survey-weighted Cox models were fitted across 20 imputed datasets and combined using Rubin's rules. Restricted cubic splines examined dose-response relationships. Complementary categorical, subgroup, and sensitivity analyses were conducted. Human umbilical vein endothelial cell (HUVEC) experiments repeated in three independent runs compared cellular responses under a regular dexamethasone schedule and four prespecified irregular schedule variants. Results: Over a median follow-up of 81 months, 714 all-cause and 229 CVD deaths occurred. Each 1-hour increase in the across-night SD of sleep midpoint, sleep onset, and total sleep time was associated with all-cause mortality HRs of 1.22 (95% CI, 1.12-1.33), 1.19 (1.11-1.29), and 1.17 (1.05-1.31), respectively. The corresponding CVD mortality HRs were 1.21 (1.09-1.35), 1.22 (1.05-1.42), and 1.16 (0.94-1.42), respectively. Each 10-point lower SRI was associated with all-cause mortality (HR, 1.29; 95% CI, 1.21-1.38) and CVD mortality (HR, 1.31; 95% CI, 1.18-1.45). Across three independent HUVEC runs, the mean response across the four prespecified irregular schedule variants showed lower core clock-gene expression, lower Griess assay absorbance, and higher inflammatory and adhesion-marker expression than the regular schedule. Conclusions: Greater night-to-night sleep irregularity was associated with higher hazards of all-cause and CVD mortality, although these associations were modest compared with those of older age, hypertension, and diabetes in the same models. The complementary cellular experiment showed differences between the regular dexamethasone schedule and the prespecified irregular schedule set.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.